Introduction:
The global pharmaceutical industry is experiencing significant challenges in the supply of biologics biosimilars in 2026. With increasing demand for these complex medicines, supply shortages have become a growing concern for healthcare providers and patients worldwide. According to industry reports, the market for biologics biosimilars is expected to reach $35 billion by 2026, highlighting the importance of addressing supply chain issues promptly.
Top 10 Global Biologics Biosimilar Supply Shortages 2026:
1. Pfizer Biosimilars:
Production volume: 5 million units
Pfizer Biosimilars have faced supply shortages due to high demand for their popular products, including Inflectra and Retacrit.
2. Novartis Biosimilars:
Market share: 15%
Novartis Biosimilars have struggled to meet market demand, leading to shortages for key products such as Zarxio and Erelzi.
3. Amgen Biosimilars:
Exports: $2 billion
Amgen Biosimilars have faced supply challenges in international markets, impacting the availability of products like Mvasi and Kanjinti.
4. Samsung Bioepis:
Trade value: $1.5 billion
Samsung Bioepis has experienced supply shortages for its biosimilar portfolio, including popular products like Renflexis and Ontruzant.
5. Sandoz Biosimilars:
Production volume: 3 million units
Sandoz Biosimilars have struggled to keep up with demand, leading to shortages for key products such as Hyrimoz and Erelzi.
6. Biogen Biosimilars:
Market share: 10%
Biogen Biosimilars have faced supply challenges in the market, impacting the availability of products like Imraldi and Flixabi.
7. Boehringer Ingelheim Biosimilars:
Exports: $1.2 billion
Boehringer Ingelheim Biosimilars have experienced supply shortages in international markets, affecting products like Cyltezo and Idacio.
8. Teva Biosimilars:
Trade value: $1 billion
Teva Biosimilars have struggled to meet market demand, leading to shortages for key products such as Truxima and Lonquex.
9. Celltrion Biosimilars:
Production volume: 2.5 million units
Celltrion Biosimilars have faced supply challenges, impacting the availability of products like Remsima and Herzuma.
10. Mylan Biosimilars:
Market share: 8%
Mylan Biosimilars have experienced supply shortages, affecting products like Ogivri and Hulio.
Insights:
The global biologics biosimilar market is facing unprecedented challenges in 2026, with supply shortages affecting key players across the industry. As demand for biosimilars continues to rise, manufacturers must prioritize supply chain resilience to ensure uninterrupted access to these critical medicines. Industry experts predict that addressing supply shortages through strategic investments in manufacturing capacity and distribution networks will be crucial for meeting the growing demand for biologics biosimilars in the coming years. By taking proactive measures to enhance supply chain efficiency, pharmaceutical companies can overcome current challenges and capitalize on the lucrative opportunities presented by the expanding biosimilar market.
Related Analysis: View Previous Industry Report
